| Site Map |
| References |
| Glossary |
Media
Center
Home
| Hepatitis B Video |
| Materials to Download |
| Hepatitis B Resources |
| Community Events |
| Hepatitis B Treatment Product Information |
To view press releases or news articles about EPIVIR-HBV, please visit the GlaxoSmithKline Media Room at http://www.gsk.com/media/pressreleases.htm.
Please click here to view the news article, "GlaxoSmithKline Study Shows Need for More Hepatitis B Education."
EPIVIR-HBV is indicated for the treatment of chronic hepatitis B associated with viral replication and active liver inflammation in adults and children 2-17 years.